6 research outputs found
Entrepreneurship Education in Nigeria: Challenges and Ways Forward
No full textThe rapid increase in population growth of graduates in our schools had resulted into unemployment of tertiary institution graduates. This is because the government and private sector cannot have enough jobs to accommodate them. Consequently, entrepreneurship education was introduced in our tertiary institutions of learning to address this issue. Entrepreneurship education is the acquisition of skills, ability, competence which equip the recipients with initiative, creativity, risk taking ability, enthusiasm, independence, and vision for business venture. Graduates equip with knowledge and skills of entrepreneurship education would be aware of the existing businesses and think of it as alternative. Despite the advantages of the entrepreneurship education, it is faced with some challenges. These challenges among others are unavailable fund for teachings in practical terms for entrepreneurial education and start up and expansion of business ventures, inadequate facilities or equipments, and poor enabling environment for business. Finally, ways forward were suggested to address these challenges
Carcinoma of the colon in children with metastases to the duodenum: Report of two cases and management reflections
No full textAbstractGastrointestinal and colonic malignancies in children are rarely documented and almost always are diagnosed at an advanced stage of the disease with poor prognosis and outcomes. Due to rarity and paucity of data on these tumors and low index of suspicion among clinicians, these tumors are usually diagnosed at an advance stage. Therefore, the objective of this report is to present an eight-year-old male child with mucinous adenocarcinoma of recto-sigmoid colon with metastasis to the duodenum, liver, retro-peritoneal spaces and the anterior abdominal wall and sixteen-year-old female patient with poorly differentiated adenocarcinoma of the transverse colon with metastasis to the duodenum, omentum, mesentery, small intestine, visceral and parietal peritonea (carcinomatosis). Both patients had Duke's stage D tumors. Both patients were operated on at children surgical unit of Murtala Mohammad Specialist Hospital, Kano in northern Nigeria. Diagnosis, surgical management and outcomes are discussed. Review of selected literature and management reflections of this rare fatal lesion in children are presented
Impact of the COVID-19 pandemic on patients with paediatric cancer in low-income, middle-income and high-income countries: a multicentre, international, observational cohort study
No full textOBJECTIVES: Paediatric cancer is a leading cause of death for children. Children in low-income and middle-income countries (LMICs) were four times more likely to die than children in high-income countries (HICs). This study aimed to test the hypothesis that the COVID-19 pandemic had affected the delivery of healthcare services worldwide, and exacerbated the disparity in paediatric cancer outcomes between LMICs and HICs. DESIGN: A multicentre, international, collaborative cohort study. SETTING: 91 hospitals and cancer centres in 39 countries providing cancer treatment to paediatric patients between March and December 2020. PARTICIPANTS: Patients were included if they were under the age of 18 years, and newly diagnosed with or undergoing active cancer treatment for Acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, Wilms' tumour, sarcoma, retinoblastoma, gliomas, medulloblastomas or neuroblastomas, in keeping with the WHO Global Initiative for Childhood Cancer. MAIN OUTCOME MEASURE: All-cause mortality at 30 days and 90 days. RESULTS: 1660 patients were recruited. 219 children had changes to their treatment due to the pandemic. Patients in LMICs were primarily affected (n=182/219, 83.1%). Relative to patients with paediatric cancer in HICs, patients with paediatric cancer in LMICs had 12.1 (95% CI 2.93 to 50.3) and 7.9 (95% CI 3.2 to 19.7) times the odds of death at 30 days and 90 days, respectively, after presentation during the COVID-19 pandemic (p<0.001). After adjusting for confounders, patients with paediatric cancer in LMICs had 15.6 (95% CI 3.7 to 65.8) times the odds of death at 30 days (p<0.001). CONCLUSIONS: The COVID-19 pandemic has affected paediatric oncology service provision. It has disproportionately affected patients in LMICs, highlighting and compounding existing disparities in healthcare systems globally that need addressing urgently. However, many patients with paediatric cancer continued to receive their normal standard of care. This speaks to the adaptability and resilience of healthcare systems and healthcare workers globally
Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
No full textIntroduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68); p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61); p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03); p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86); p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91); p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84); p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer
Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
No full textChildhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality
Twelve-month observational study of children with cancer in 41 countries during the COVID-19 pandemic
No full textIntroduction Childhood cancer is a leading cause of death. It is unclear whether the COVID-19 pandemic has impacted childhood cancer mortality. In this study, we aimed to establish all-cause mortality rates for childhood cancers during the COVID-19 pandemic and determine the factors associated with mortality. Methods Prospective cohort study in 109 institutions in 41 countries. Inclusion criteria: children <18 years who were newly diagnosed with or undergoing active treatment for acute lymphoblastic leukaemia, non-Hodgkin's lymphoma, Hodgkin lymphoma, retinoblastoma, Wilms tumour, glioma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, medulloblastoma and neuroblastoma. Of 2327 cases, 2118 patients were included in the study. The primary outcome measure was all-cause mortality at 30 days, 90 days and 12 months. Results All-cause mortality was 3.4% (n=71/2084) at 30-day follow-up, 5.7% (n=113/1969) at 90-day follow-up and 13.0% (n=206/1581) at 12-month follow-up. The median time from diagnosis to multidisciplinary team (MDT) plan was longest in low-income countries (7 days, IQR 3-11). Multivariable analysis revealed several factors associated with 12-month mortality, including low-income (OR 6.99 (95% CI 2.49 to 19.68)p<0.001), lower middle income (OR 3.32 (95% CI 1.96 to 5.61)p<0.001) and upper middle income (OR 3.49 (95% CI 2.02 to 6.03)p<0.001) country status and chemotherapy (OR 0.55 (95% CI 0.36 to 0.86)p=0.008) and immunotherapy (OR 0.27 (95% CI 0.08 to 0.91)p=0.035) within 30 days from MDT plan. Multivariable analysis revealed laboratory-confirmed SARS-CoV-2 infection (OR 5.33 (95% CI 1.19 to 23.84)p=0.029) was associated with 30-day mortality. Conclusions Children with cancer are more likely to die within 30 days if infected with SARS-CoV-2. However, timely treatment reduced odds of death. This report provides crucial information to balance the benefits of providing anticancer therapy against the risks of SARS-CoV-2 infection in children with cancer. © 2022 BMJ Publishing Group. All rights reserved
